Every 8-K that AtaiBeckley Inc. (ATAI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ATAI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ATAI filings page.
AtaiBeckley Inc. (ATAI) completed its merger with Eli Lilly and Company, making AtaiBeckley a wholly owned subsidiary of Eli Lilly. Each share of common stock outstanding immediately before closing was converted into the right to receive $6.75 in cash plus one contingent value right (CVR) per share, less applicable tax withholding.
Each CVR entitles holders to receive up to an additional $2.50 in cash per share if specified milestones are achieved: up to $1.00 upon initiation of a Phase 3 trial of VLS-01 by the 4th anniversary of closing, up to $0.50 upon U.S. regulatory approval and DEA rescheduling of BPL-003 by the 5th anniversary, and up to $1.00 upon U.S. regulatory approval and DEA rescheduling of VLS-01 by the 7th anniversary. The CVRs are largely non-transferable, unregistered, unlisted, and carry no voting, dividend, or equity rights.
Following the change in control, AtaiBeckley requested suspension of Nasdaq trading and delisting of its common stock and plans to terminate its SEC registration and reporting obligations. The pre-merger board and executive officers resigned at closing, and the directors and officers of the merger subsidiary, including President Jonathan R. Haug, assumed those roles at AtaiBeckley.
AtaiBeckley Inc. (ATAI) reports that stockholders approved the adoption of the Merger Agreement with Eli Lilly and Company at a virtual special meeting held on September 8, 2026. Of 370,864,669 shares of common stock outstanding as of the August 7, 2026 record date, 243,351,557 shares (approximately 65.6%) were present, constituting a quorum.
The Merger Proposal received 237,762,253 votes for, 5,033,755 against, and 555,549 abstentions. An Adjournment Proposal was also approved but was not acted upon. Assuming satisfaction or waiver of remaining conditions, AtaiBeckley expects the merger to be consummated on September 11, 2026, subject to the risks and uncertainties described.
AtaiBeckley Inc. (ATAI) reports regulatory progress for its pending acquisition by Eli Lilly and Company under their July 15, 2026 Merger Agreement, under which Albali Acquisition Corporation will merge with and into AtaiBeckley, leaving AtaiBeckley as a wholly owned subsidiary of Eli Lilly.
The U.S. antitrust waiting period under the Hart-Scott-Rodino Antitrust Improvements Act for the merger expired at 11:59 p.m. Eastern Time on August 28, 2026. The U.K. Competition and Markets Authority indicated on August 21, 2026 that it then had no further questions regarding the merger. The Australian Competition and Consumer Commission determined on August 27, 2026 that the merger may be consummated, subject to a 14‑calendar day waiting period scheduled to expire at 10:00 a.m. Eastern Time on September 10, 2026. The company highlights risks that the merger may be delayed or may not close, including potential failure to obtain stockholder approval or satisfy closing conditions.
AtaiBeckley Inc. agreed to be acquired by Eli Lilly and Company via a merger under which each AtaiBeckley share will receive $6.75 in cash at closing plus one non-transferable contingent value right (CVR) for up to an additional $2.50 in cash per share.
Each CVR pays cash only if milestones are met: up to $1.00 per share for initiation of a Phase 3 trial of VLS-01 within four years of closing, $0.50 for U.S. approval and DEA rescheduling of BPL-003 within five years, and $1.00 for U.S. approval and rescheduling of VLS-01 within seven years.
The upfront price values AtaiBeckley at about $2.8 billion, with CVRs adding up to $1.0 billion more, representing roughly a 40% premium to the 30-day VWAP. Closing, targeted for the third quarter, is subject to stockholder and regulatory approvals and other conditions; a $104.3 million termination fee and voting agreements covering about 15% of shares are included in the deal terms.
AtaiBeckley Inc. reported the results of its annual stockholder meeting. As of the April 9, 2026 record date, 366,916,896 common shares were outstanding and entitled to vote, and 203,908,561 shares were represented at the meeting, constituting a quorum.
Stockholders elected Class I directors Sabrina Martucci Johnson, Amir Kalali, M.D., and Andrea Heslin Smiley to serve until the 2029 annual meeting and until their successors are elected and qualified. Stockholders also ratified the appointment of Deloitte & Touche LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
AtaiBeckley Inc. reported that it will participate in several investor conferences in June 2026, including the Jefferies Global Healthcare Conference, the Oppenheimer CNS and Neuro-Muscular Summit, the 7th Annual HCW Neuro Perspectives Hybrid Conference, and UBS Virtual CNS Day. Management plans to discuss program updates, including initiation of the BPL-003 Phase 3 pivotal ReConnection program, along with other topics. Webcasts for certain events will be available through the company’s investor relations website. The communication is furnished as a Regulation FD disclosure and is accompanied by standard cautionary language about forward-looking statements and related risks.
AtaiBeckley Inc. reported first quarter 2026 results showing continued investment in its mental health pipeline and a solid cash position. Revenue was $954 thousand, while research and development expenses rose to $17.4 million and general and administrative expenses to $14.4 million, reflecting higher clinical and personnel costs.
Net loss attributable to stockholders was $29.8 million, compared with $26.4 million a year earlier, as the company advances BPL-003 into a Phase 3 ReConnection program for treatment-resistant depression and continues Phase 2 development for VLS-01 and EMP-01. Cash, cash equivalents and short-term securities totaled $209.9 million as of March 31, 2026, and are expected to fund operations into 2029.